Integrated Biopharma, Inc.
INBP
$0.32
$0.000.00%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 12.69M | 14.18M | 13.95M | 12.61M | 13.62M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.69M | 14.18M | 13.95M | 12.61M | 13.62M |
| Cost of Revenue | 11.67M | 12.71M | 12.40M | 11.44M | 12.25M |
| Gross Profit | 1.02M | 1.47M | 1.55M | 1.17M | 1.37M |
| SG&A Expenses | 856.00K | 880.00K | 812.00K | 969.00K | 881.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.53M | 13.59M | 13.21M | 12.41M | 13.13M |
| Operating Income | 163.00K | 589.00K | 739.00K | 202.00K | 490.00K |
| Income Before Tax | 196.00K | 595.00K | 778.00K | 185.00K | 504.00K |
| Income Tax Expenses | 73.00K | 773.00K | 167.00K | 69.00K | 245.00K |
| Earnings from Continuing Operations | 123.00K | -178.00K | 611.00K | 116.00K | 259.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 123.00K | -178.00K | 611.00K | 116.00K | 259.00K |
| EBIT | 163.00K | 589.00K | 739.00K | 202.00K | 490.00K |
| EBITDA | 240.00K | 660.00K | 815.00K | 285.00K | 575.00K |
| EPS Basic | 0.00 | -0.01 | 0.02 | 0.00 | 0.01 |
| Normalized Basic EPS | 0.00 | 0.01 | 0.02 | 0.00 | 0.01 |
| EPS Diluted | 0.00 | -0.01 | 0.02 | 0.00 | 0.01 |
| Normalized Diluted EPS | 0.00 | 0.01 | 0.01 | 0.00 | 0.01 |
| Average Basic Shares Outstanding | 31.06M | 30.61M | 30.30M | 30.17M | 30.10M |
| Average Diluted Shares Outstanding | 31.42M | 30.61M | 31.51M | 31.30M | 30.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |